CI Canadian Convertible Bond ETF Common (CXF) Competitors C$10.31 -0.03 (-0.29%) As of 08/22/2025 03:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesBuy This Stock CXF vs. IPA, CRDL, APM, GXE, GPH, MDNA, WMD, EQ, SGW, and CGCShould you be buying CI Canadian Convertible Bond ETF Common stock or one of its competitors? The main competitors of CI Canadian Convertible Bond ETF Common include ImmunoPrecise Antibodies (IPA), Cardiol Therapeutics (CRDL), Andean Precious Metals (APM), Gear Energy (GXE), Graphite One (GPH), Medicenna Therapeutics (MDNA), WeedMD (WMD), EQ (EQ), Shoal Games (SGW), and Canadian Gold (CGC). These companies are all part of the "pharmaceutical products" industry. CI Canadian Convertible Bond ETF Common vs. Its Competitors ImmunoPrecise Antibodies Cardiol Therapeutics Andean Precious Metals Gear Energy Graphite One Medicenna Therapeutics WeedMD EQ Shoal Games Canadian Gold CI Canadian Convertible Bond ETF Common (TSE:CXF) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings. Which has preferable earnings and valuation, CXF or IPA? CI Canadian Convertible Bond ETF Common has higher earnings, but lower revenue than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCI Canadian Convertible Bond ETF CommonN/AN/AN/AN/AN/AImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89-7.30 Is CXF or IPA more profitable? Company Net Margins Return on Equity Return on Assets CI Canadian Convertible Bond ETF CommonN/A N/A N/A ImmunoPrecise Antibodies N/A N/A N/A Does the media refer more to CXF or IPA? In the previous week, CI Canadian Convertible Bond ETF Common had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 1 mentions for CI Canadian Convertible Bond ETF Common and 0 mentions for ImmunoPrecise Antibodies. CI Canadian Convertible Bond ETF Common's average media sentiment score of 0.75 beat ImmunoPrecise Antibodies' score of 0.00 indicating that CI Canadian Convertible Bond ETF Common is being referred to more favorably in the media. Company Overall Sentiment CI Canadian Convertible Bond ETF Common Positive ImmunoPrecise Antibodies Neutral SummaryCI Canadian Convertible Bond ETF Common beats ImmunoPrecise Antibodies on 2 of the 3 factors compared between the two stocks. Get CI Canadian Convertible Bond ETF Common News Delivered to You Automatically Sign up to receive the latest news and ratings for CXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CXF vs. The Competition Export to ExcelMetricCI Canadian Convertible Bond ETF CommonPharmaceutical Preparations IndustryManufacturing SectorTSE ExchangeMarket CapC$52.12MC$835.92MC$2.59BC$6.37BDividend Yield4.84%4.84%2.55%6.72%P/E RatioN/A1.1822.0473.11Price / SalesN/A26.3571.831,702.26Price / CashN/A19.5623.4783.29Price / BookN/A6.6431.914.91Net IncomeN/A-C$4.94MC$31.01MC$301.20M7 Day Performance0.39%1.64%1.08%1.35%1 Month Performance-0.29%2.55%1.18%1.88%1 Year Performance3.93%10.89%29.29%27.39% CI Canadian Convertible Bond ETF Common Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CXFCI Canadian Convertible Bond ETF CommonN/AC$10.31-0.3%N/A+3.9%C$52.12MN/A0.0090News CoverageIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownCRDLCardiol TherapeuticsN/AC$1.83-1.1%N/A-41.3%C$151.85MN/A-3.6020News CoverageHigh Trading VolumeAPMAndean Precious Metals2.486 of 5 starsC$1.29+7.5%C$2.00+55.0%+22.9%C$135.47MC$154.78M2.5530GXEGear EnergyN/AN/AN/AN/AC$126.52MC$134.93M10.391,310GPHGraphite OneN/AC$1.02+4.1%N/A+3.8%C$103.28MN/A-14.6720News CoverageMDNAMedicenna TherapeuticsN/AC$1.08flatN/A-47.9%C$80.80MC$4.87K-2.9720WMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpEQEQN/AC$0.97flatN/A-13.4%C$67.51MC$9.70M-14.4840High Trading VolumeSGWShoal GamesN/AC$0.50+42.9%N/A+0.0%C$65.56MC$106.98K-12.5040Gap UpCGCCanadian GoldN/AC$0.31-1.6%N/A+105.2%C$56.53MC$36.51M-10.173,150High Trading Volume Related Companies and Tools Related Companies IPA Alternatives CRDL Alternatives APM Alternatives GXE Alternatives GPH Alternatives MDNA Alternatives WMD Alternatives EQ Alternatives SGW Alternatives CGC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:CXF) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CI Canadian Convertible Bond ETF Common Please log in to your account or sign up in order to add this asset to your watchlist. Share CI Canadian Convertible Bond ETF Common With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access